Recombinant Anti-VEGFR2 Fully Human Monoclonal Antibody (JY025) Injection Combined With Gefitinib/Erlotinib as First-line Treatment Phase II and III Clinical Trials on the Efficacy and Safety of Patients With EGFR-mutant NSCLC
Latest Information Update: 27 Sep 2023
At a glance
- Drugs JY 025 (Primary) ; Erlotinib; Gefitinib
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Beijing Dongfang Biotech
- 12 May 2021 New trial record